News

US FDA accepts Novo Nordisk's application for oral Wegovy for weight loss
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
Active ingredient in weight loss drug Wegovy may help treat fatty liver disease
The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to new ...
Managed Healthcare Executive52m
FDA Sets Action Date for Oral Wegovy for Weight Loss
A decision is expected in the fourth quarter of 2025.
Novo Nordisk shares jump as FDA accepts Wegovy pill application
Investing.com -- Novo Nordisk (NYSE: NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the ...
Exclusive: HSBC Asset Management's global head of sustainability to depart
The top sustainable finance executive at HSBC's asset management division is leaving the firm, HSBC said on Friday, the ...
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Novo Nordisk says oral version of Wegovy accepted for FDA review
Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.
Novo Nordisk Says FDA Accepted New Drug Application for Wegovy Pill
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
Healthcare Dive3h
Cigna doubles down on GLP-1 support programs with two new launches
The company’s health services division Evernorth is doubling down on a reliable growth area: assuaging payer concerns around ...
Becker's Hospital Review6h
CVS Caremark selects Wegovy as preferred GLP-1 for commercial formularies
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...